A small-molecule SUMOylation inhibitor activates antitumor immune responses and potentiates immune therapies in preclinical models
Eric S. Lightcap, Dennis Huszar, Beryl A. Hatton(Presage Biosciences (United States)), Pengfei Yu(Chinese Academy of Sciences), Hisashi Imaichi(AVEO Oncology (United States)), James Minissale(Takeda (United States)), Erik Koenig(Millennium Engineering and Integration (United States)), Katherine Galvin(Takeda (United States)), Vaishali Shinde(AVEO Oncology (United States)), Stephen Grossman(Takeda (United States)), Mithun Khattar(AVEO Oncology (United States)), Michael A. Milhollen(Millennium Engineering and Integration (United States)), Yu Fu(AVEO Oncology (United States)), Richard A. Klinghoffer(Rosetta Stone (United States)), Steven Langston(Takeda (United States)), James M. Gavin(Millennium Engineering and Integration (United States)), Xingyue He(Takeda (United States)), Jessica Riceberg(Takeda (United States)), James Garnsey(Millennium Engineering and Integration (United States)), Dylan B. England(Takeda (United States)), Zhen Lu(University of Pennsylvania), Kristina Xega(Takeda (United States)), Cong Li(Shihezi University), Xiaofeng Yang(Millennium Engineering and Integration (United States)), Hongru Zhang(University of Pennsylvania), Pooja Shah(Takeda (United States)), Sai Murali Krishna Pulukuri(Takeda (United States)), Gary Shapiro(AVEO Oncology (United States)), Keli Song(Takeda (United States)), Serge Y. Fuchs(University of Pennsylvania)
Cited by 139
Related Papers
Src family kinases are required for integrin but not PDGFR signal transduction
|The EMBO Journal|1999|729
Substrate-Assisted Inhibition of Ubiquitin-like Protein-Activating Enzymes: The NEDD8 E1 Inhibitor MLN4924 Forms a NEDD8-AMP Mimetic In Situ
|Molecular Cell|2010|461
A small-molecule inhibitor of the ubiquitin activating enzyme for cancer treatment
|Nature Medicine|2018|453